Antimicrobial Peptidomimetics Prevent the Development of Resistance against Gentamicin and Ciprofloxacin in Staphylococcus and Pseudomonas Bacteria
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241914966 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Katrina Browne und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, University of New South Wales (UNSW) Sydney, Sydney 2052, Australia. Hauptthemen laut MEDLINE: Peptidomimetics, Anti-Infective Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Bacteria readily acquire resistance to traditional antibiotics, resulting in pan-resistant strains with no available treatment. Antimicrobial resistance is a global challenge and without the development of effective antimicrobials, the foundation of modern medicine is at risk. Combination therapies such as antibiotic–antibiotic and antibiotic–adjuvant combinations are strategies used to combat antibiotic resistance. Current research focuses on antimicrobial peptidomimetics as adjuvant compounds, due to their promising activity against antibiotic-resistant bacteria. Here, for the first time we demonstrate that antibiotic–peptidomimetic combinations mitigate the development of antibiotic resistance in Staphylococcus aureus and Pseudomonas aeruginosa. When ciprofloxacin and gentamicin were passaged individually at sub-inhibitory concentrations for 10 days, the minimum inhibitory concentrations (MICs) increased up to 32-fold and 128-fold for S. aureus and P. aeruginosa, respectively. In contrast, when antibiotics were passaged in combination with peptidomimetics (Melimine, Mel4, RK758), the MICs of both antibiotics and peptidomimetics remained constant, indicating these combinations were able to mitigate the development of antibiotic-resistance. Furthermore, antibiotic–peptidomimetic combinations demonstrated synergistic activity against both Gram-positive and Gram-negative bacteria, reducing the concentration needed for bactericidal activity. This has significant potential clinical applications—including preventing the spread of antibiotic-resistant strains in hospitals and communities, reviving ineffective antibiotics, and lowering the toxicity of antimicrobial chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry, University of New South Wales (UNSW) Sydney, Sydney 2052, Australia.
- Surgical and Orthopaedic Research Laboratories (SORL), Prince of Wales Clinical School, Prince of Wales Hospital, University of New South Wales (UNSW), Randwick 2031, Australia.
- School of Optometry and Vision Science, University of New South Wales (UNSW) Sydney, Sydney 2052, Australia.
ORCID-Profile: Rajesh Kuppusamy, William R Walsh, David StC Black, Mark D P Willcox, Naresh Kumar, Renxun Chen
Förderung
- National Health and Medical Research Council
Zitieren
APA
Browne, K., Kuppusamy, R., Walsh, W. R., Black, D. S., Willcox, M. D. P., Kumar, N., & Chen, R. (2023). Antimicrobial Peptidomimetics Prevent the Development of Resistance against Gentamicin and Ciprofloxacin in Staphylococcus and Pseudomonas Bacteria. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914966
Vancouver
Browne K, Kuppusamy R, Walsh WR, Black DS, Willcox MDP, Kumar N, et al. Antimicrobial Peptidomimetics Prevent the Development of Resistance against Gentamicin and Ciprofloxacin in Staphylococcus and Pseudomonas Bacteria. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914966
BibTeX
@article{Browne2023,
author = {Browne, Katrina and Kuppusamy, Rajesh and Walsh, William R and Black, David StC and Willcox, Mark D P and Kumar, Naresh and Chen, Renxun},
title = {Antimicrobial Peptidomimetics Prevent the Development of Resistance against Gentamicin and Ciprofloxacin in Staphylococcus and Pseudomonas Bacteria},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241914966}
}
EUVIMED